journal article·2025-08Open access

Responsive ROS‐Augmented Prodrug Hybridization Nanoassemblies for Multidimensionally Synergitic Treatment of Hepatocellular Carcinoma in Cascade Assaults

Yingjie Zeng, Yuening Cao, Senmiao Ren, Chaozheng Zhang, Jianan Liu, Ke Liu, Yan Wang, Hongyu Chen, Fengjiao Zhou, Xiuli Yang, Xian Ge, Tingting Zhang, Tianbao Wang, Yao He, Defang Li, Chuantao Zhang, Jun Lu

Advanced Science· Volume 12· Issue 29

Abstract

Abstract The rapid deterioration and progression of hepatocellular carcinoma (HCC) is intimately associated with copper ion overload, and integrating the cuproptosis mechanism for the treatment of HCC presents a promising prospect. Nevertheless, cell death complexity renders efficient removal of all HCC cells insufficient solely relying on the cuproptosis pathway. Herein, the GSH‐responsive prodrug hybridization nanoassembly CA‐4S 2 @ES‐Cu is exploited, which targets the delivery of copper ions to mitochondria via Elesclomol, contributing to mitochondrial dysfunction and evoking cuproptosis. Simultaneously, CA‐4S 2 depletes GSH to release CA‐4, disrupting microtubule function and suppressing HCC cell proliferation and angiogenesis, to realize a dual attack against copper ion‐mediated deterioration and metastasis of HCC. Furthermore, both in the HCC mouse model synergistically elicit oxidative stress to amplify the cuproptosis effect and release activated immunogenetic cell death to initiate a vigorous antitumor immune response in cascade assault modality. Conclusively, the multilevel synergistic assault penetrates the limitations of single therapy and implements a multidimensional targeted treatment for HCC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Endoplasmic Reticulum Stress and Disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Southwestern Chinese Medicine Resources School of Pharmacy Chengdu University of Traditional Chinese Medicine Chengdu 611137 China

Department of Respiratory Medicine Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075 China

College of Pharmacy Hebei University of Chinese Medicine Shijiazhuang 050200 China

Sichuan Clinical Research Center for Cancer Sichuan Cancer Hospital & Institute Sichuan Cancer Center Affiliated Cancer Hospital of University of Electronic Science and Technology of China Chengdu 610041 China

Funding

National Natural Science Foundation of China · Chengdu Science and Technology Bureau

References (44)

Show source-provided references
1. 10.1016/j.ccr.2023.21515610.1016/j.ccr.2023.215156 ↗
2. 10.1016/j.canlet.2023.21634810.1016/j.canlet.2023.216348 ↗
3. 10.1007/s00535030000510.1007/s005350300005 ↗
4. 10.1371/journal.pone.023737010.1371/journal.pone.0237370 ↗
5. Liao Q. · Mol. Cell. · 2024 · 132
6. 10.1016/j.cej.2021.13014710.1016/j.cej.2021.130147 ↗
7. 10.1073/pnas.181747311610.1073/pnas.1817473116 ↗
8. 10.1038/s41467-021-27559-z10.1038/s41467-021-27559-z ↗
9. 10.1186/s13046-022-02485-010.1186/s13046-022-02485-0 ↗
10. 10.1039/C8MT00182K10.1039/C8MT00182K ↗
11. O'Reilly A. · J. Immunother. Cancer · 2024 · 12
12. 10.1002/advs.20240104710.1002/advs.202401047 ↗
13. Dark G. G. · Cancer Res. · 1997 · 57 · 1829
14. 10.1172/JCI2458610.1172/JCI24586 ↗
15. 10.1002/advs.20231030910.1002/advs.202310309 ↗
16. 10.1002/adfm.20240202210.1002/adfm.202402022 ↗
17. 10.1186/s40364-024-00677-810.1186/s40364-024-00677-8 ↗
18. 10.1186/s13046-024-03133-510.1186/s13046-024-03133-5 ↗
19. 10.1016/j.jconrel.2024.11.05310.1016/j.jconrel.2024.11.053 ↗
20. 10.1038/s41467-023-39245-310.1038/s41467-023-39245-3 ↗
21. 10.1038/s41467-024-54469-710.1038/s41467-024-54469-7 ↗
22. 10.1002/advs.20200430310.1002/advs.202004303 ↗
23. 10.3390/cancers1422571310.3390/cancers14225713 ↗
24. 10.1016/j.jare.2024.03.00210.1016/j.jare.2024.03.002 ↗
25. 10.1002/adma.20180595510.1002/adma.201805955 ↗
26. 10.1002/adfm.20180069210.1002/adfm.201800692 ↗
27. 10.1016/j.ejmech.2024.11715310.1016/j.ejmech.2024.117153 ↗
28. 10.1016/j.ejmech.2024.11618310.1016/j.ejmech.2024.116183 ↗
29. 10.1038/s41589-019-0291-910.1038/s41589-019-0291-9 ↗
30. 10.1126/science.abf052910.1126/science.abf0529 ↗
31. 10.1016/j.cej.2024.15740810.1016/j.cej.2024.157408 ↗
32. 10.1016/j.phymed.2022.15401510.1016/j.phymed.2022.154015 ↗
33. 10.1038/s41590-022-01132-210.1038/s41590-022-01132-2 ↗
34. 10.1002/advs.20230998410.1002/advs.202309984 ↗
35. 10.1002/adma.20240497110.1002/adma.202404971 ↗
36. 10.1016/j.cytogfr.2013.05.00110.1016/j.cytogfr.2013.05.001 ↗
37. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
38. 10.1038/s43018-020-0042-610.1038/s43018-020-0042-6 ↗
39. 10.1038/s41419-022-05201-010.1038/s41419-022-05201-0 ↗
40. 10.1016/j.phrs.2022.10641510.1016/j.phrs.2022.106415 ↗
41. 10.1002/adma.20190427810.1002/adma.201904278 ↗
42. 10.1016/j.biopha.2023.11578410.1016/j.biopha.2023.115784 ↗
43. 10.1186/s13046-018-0727-110.1186/s13046-018-0727-1 ↗
44. 10.1016/j.bioactmat.2022.06.01810.1016/j.bioactmat.2022.06.018 ↗